Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571938 | 0.80 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL6574891 | 0.76 | P2RX7 (0.40) | LMNAEPHX2P2RX7 | |
| SCHEMBL6573572 | 0.74 | P2RX7 (0.41) | SCN9AHSD11B1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6573186 | 0.73 | P2RX7 (0.61) | P2RX7 | |
| SCHEMBL6571362 | 0.73 | P2RX7 (0.41) | LMNAEPHX2P2RX7 | |
| SCHEMBL6572489 | 0.72 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL6574791 | 0.72 | P2RX7 (0.41) | ALDH1A1LMNAEPHX2P2RX7 | |
| SCHEMBL6572556 | 0.71 | P2RX7 (0.61) | P2RX7 | |
| SCHEMBL6572993 | 0.71 | P2RX7 (0.58) | P2RX7 | |
| SCHEMBL6574980 | 0.71 | P2RX7 (0.50) | LMNAEPHX2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720452-B2 | SUBSTITUTED BENZMIDE-N-METHYL ADMANATANE DERIVATIVES USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ASTRAZENECA AB (SE) | 2004-04-13 | — | — | US | disclosed |
| EP-1240132-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20020193414-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | US | disclosed |
| EP-1240132-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042194-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193414-A1 | Adamantane derivatives | APP, ADORA1, ADAM17 | SCN9A 562/4885HSD11B1 317/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.